Difei Yang
Stock Analyst at Mizuho
(2.14)
# 2,885
Out of 5,131 analysts
29
Total ratings
31.03%
Success rate
11.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.52 | +31.58% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $14.35 | +1,293.73% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $1.10 | +3,354.55% | 1 | Apr 26, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $25.32 | +105.37% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $23.83 | +571.42% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $7.93 | +76.54% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $39.71 | +1,222.09% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.31 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $14.59 | +91.91% | 1 | Feb 13, 2018 | |
| HRTX Heron Therapeutics | Initiates: Buy | $28 | $1.39 | +1,914.39% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.52
Upside: +31.58%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $14.35
Upside: +1,293.73%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.10
Upside: +3,354.55%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $25.32
Upside: +105.37%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $23.83
Upside: +571.42%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $7.93
Upside: +76.54%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $39.71
Upside: +1,222.09%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.31
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $14.59
Upside: +91.91%
Heron Therapeutics
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.39
Upside: +1,914.39%